Insulet Co. (NASDAQ:PODD) Shares Purchased by Daiwa Securities Group Inc.

Daiwa Securities Group Inc. raised its position in Insulet Co. (NASDAQ:PODD) by 22.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 15,114 shares of the medical instruments supplier’s stock after purchasing an additional 2,736 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Insulet were worth $3,946,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the business. Mizuho Securities USA LLC grew its holdings in Insulet by 5,928.1% in the 3rd quarter. Mizuho Securities USA LLC now owns 325,821 shares of the medical instruments supplier’s stock worth $75,835,000 after buying an additional 320,416 shares in the last quarter. Raymond James Financial Inc. acquired a new position in Insulet during the 4th quarter worth $69,433,000. Alecta Tjanstepension Omsesidigt bought a new position in shares of Insulet in the fourth quarter worth $53,184,000. Charles Schwab Investment Management Inc. increased its holdings in shares of Insulet by 43.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 636,265 shares of the medical instruments supplier’s stock valued at $148,091,000 after purchasing an additional 193,839 shares during the period. Finally, Westfield Capital Management Co. LP raised its stake in shares of Insulet by 27.6% during the third quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier’s stock valued at $175,697,000 after purchasing an additional 163,388 shares in the last quarter.

Insider Activity

In other news, EVP Eric Benjamin sold 12,394 shares of Insulet stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the transaction, the executive vice president now owns 11,383 shares in the company, valued at approximately $3,187,240. The trade was a 52.13 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.47% of the company’s stock.

Wall Street Analyst Weigh In

PODD has been the subject of a number of recent analyst reports. Citigroup increased their target price on shares of Insulet from $310.00 to $355.00 and gave the company a “buy” rating in a research report on Friday, February 21st. JPMorgan Chase & Co. increased their price objective on shares of Insulet from $280.00 to $330.00 and gave the company an “overweight” rating in a report on Thursday, December 12th. Raymond James reissued an “outperform” rating and set a $328.00 target price (up previously from $294.00) on shares of Insulet in a report on Friday, February 21st. Canaccord Genuity Group increased their price target on Insulet from $304.00 to $324.00 and gave the company a “buy” rating in a research note on Friday, February 21st. Finally, Wells Fargo & Company boosted their price objective on Insulet from $305.00 to $322.00 and gave the stock an “overweight” rating in a research note on Friday, February 21st. Four investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat.com, Insulet presently has a consensus rating of “Moderate Buy” and a consensus price target of $292.06.

Insulet Price Performance

NASDAQ PODD opened at $248.38 on Thursday. Insulet Co. has a 1 year low of $160.19 and a 1 year high of $289.46. The stock’s 50-day moving average price is $273.00 and its two-hundred day moving average price is $254.08. The company has a market cap of $17.44 billion, a PE ratio of 42.90, a PEG ratio of 3.62 and a beta of 1.29. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.00 by $0.15. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The business had revenue of $597.50 million for the quarter, compared to analyst estimates of $582.02 million. On average, analysts predict that Insulet Co. will post 3.92 EPS for the current year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.